Reflexão sobre questões de tradução da obra Feminist theory from margin to center, de Bell Hooks

Este trabalho tem como objetivo analisar os problemas e questões que surgiram ao longo da tradução da obra de bell hooks, Feminist Theory from margin to center. Esta tradução insere-se no Trabalho de Projeto realizado para a conclusão do Mestrado de Tradução da Faculdade de Letras da Universidade de Lisboa. Primeiramente, procedeu-se à tradução integral da obra de bell hooks, seguidamente, procedeu-se à elaboração de um glossário e, posteriormente, elaborou-se o relatório de projeto. Este relatório está dividido em quatro grandes secções que posteriormente se dividem em subsecções. Na primeira secção, está presente uma breve biografia da autora, bell hooks, elaborada para efeitos deste relatório. Na segunda e terceira secções deste relatório, foram analisados alguns aspetos relativos ao tradutor e ao seu papel e aspetos que influenciaram a tradução deste livro. A segunda aborda a questão dos tipos e géneros textuais e a terceira é dedicada ao tradutor e às suas tomadas de decisão. Na quarta secção, foram analisados os problemas encontrados ao longo da tradução, nomeadamente, os aspetos lexicais, em que se destacou a marcação de género em expressões nominais, os aspetos de textualidade, alguns aspetos culturais, os procedimentos de tradução, a tradução de citações, a atualidade da obra e a sua influência na tradução e, por fim, a utilização de notas de rodapé pelo tradutor. Encontra-se anexo ao relatório um glossário elaborado no contexto da tradução, construído de forma a uniformizar os termos especializados encontrados na obra.This work aims to discuss the problems and issues that occurred in the translation of the work by bell hooks, Feminist Theory from margin to center. This translation is integrated in the Work of Project carried out for the conclusion of the Master’s degree in Translation of the Faculty of Letters of the University of Lisbon. Firstly, I have translated the work by bell hooks in its fully extent. Subsequently, I have elaborated a glossary, and, finally I carried out writing the translation report. This report is divided in four main sections that are subsequently divided into subsections. In section one, we can find a short biography of the author, bell hooks, written for this report. In sections two and three of this report, I analyze some aspects related to the translator and the decisions that he or she must make, and the way these aspects have influenced the translation of this book. Section two regards text types and genres and section three regards the translator and the decisions he or she must make. In section four, I have analyzed the problems that were found throughout the translation, namely, the lexical aspects, in particular the gender specification in nominal expressions, the textual aspects, the cultural aspects, the translation strategies, the translation of quotations and, finally, the footnotes added by the translator. Attached to the report is a glossary elaborated during the translation in order to uniform the specialized terms found throughout the book

estudos artísticos

Crescer na intervenção e na comunicação é um dos objetivos da Revista Gama, estudos artísticos. Promove-se a comunicação, formal, dentro das regras da comunicação académica, através de textos cuja característica comum é serem escritos por artistas, sobre a obra de outros artistas. Este foi o critério base que inspirou o projeto das iniciativas associadas ao Congresso CSO (criadores sobre outras obras), que já completou seis anos de disseminação. A Revista Gama singularizou-se por convocar artistas e obras que de algum modo estariam esquecidos, desconhecidos, ou ainda pouco divulgados. Obras cuja execução tem raízes em passados mais ou menos recentes, mas que pelo excesso de discursos na contemporaneidade, não obtiveram a divulgação desejada. Este é um propósito de intervenção no conhecimento patrimonial: as obras existem, foram executadas, enriquecem o nosso património, mas há que as fazer funcionar, dar a conhecer, aos outros artistas, aos especialistas, ao grande público. Assim se reuniram neste número 6 da Revista Gama vinte e quatro artigos originais, procurando-se, na sua sequência e articulação, algumas relações de pertinência e afinidade. Olhares sobre arquivos, sobre acervos, sobre coleções, conjuntos muitas vezes fechados e em perigo de esquecimento, ou de incompreensão: uma entrada discreta que se abre para o interior de uma câmara escura, que é um espaço cheio de imagens por revelar.info:eu-repo/semantics/publishedVersio

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Characterisation of microbial attack on archaeological bone

As part of an EU funded project to investigate the factors influencing bone preservation in the archaeological record, more than 250 bones from 41 archaeological sites in five countries spanning four climatic regions were studied for diagenetic alteration. Sites were selected to cover a range of environmental conditions and archaeological contexts. Microscopic and physical (mercury intrusion porosimetry) analyses of these bones revealed that the majority (68%) had suffered microbial attack. Furthermore, significant differences were found between animal and human bone in both the state of preservation and the type of microbial attack present. These differences in preservation might result from differences in early taphonomy of the bones. © 2003 Elsevier Science Ltd. All rights reserved

ATLANTIC ANTS: a data set of ants in Atlantic Forests of South America

International audienc

NEOTROPICAL CARNIVORES: a data set on carnivore distribution in the Neotropics

Mammalian carnivores are considered a key group in maintaining ecological health and can indicate potential ecological integrity in landscapes where they occur. Carnivores also hold high conservation value and their habitat requirements can guide management and conservation plans. The order Carnivora has 84 species from 8 families in the Neotropical region: Canidae; Felidae; Mephitidae; Mustelidae; Otariidae; Phocidae; Procyonidae; and Ursidae. Herein, we include published and unpublished data on native terrestrial Neotropical carnivores (Canidae; Felidae; Mephitidae; Mustelidae; Procyonidae; and Ursidae). NEOTROPICAL CARNIVORES is a publicly available data set that includes 99,605 data entries from 35,511 unique georeferenced coordinates. Detection/non-detection and quantitative data were obtained from 1818 to 2018 by researchers, governmental agencies, non-governmental organizations, and private consultants. Data were collected using several methods including camera trapping, museum collections, roadkill, line transect, and opportunistic records. Literature (peer-reviewed and grey literature) from Portuguese, Spanish and English were incorporated in this compilation. Most of the data set consists of detection data entries (n = 79,343; 79.7%) but also includes non-detection data (n = 20,262; 20.3%). Of those, 43.3% also include count data (n = 43,151). The information available in NEOTROPICAL CARNIVORES will contribute to macroecological, ecological, and conservation questions in multiple spatio-temporal perspectives. As carnivores play key roles in trophic interactions, a better understanding of their distribution and habitat requirements are essential to establish conservation management plans and safeguard the future ecological health of Neotropical ecosystems. Our data paper, combined with other large-scale data sets, has great potential to clarify species distribution and related ecological processes within the Neotropics. There are no copyright restrictions and no restriction for using data from this data paper, as long as the data paper is cited as the source of the information used. We also request that users inform us of how they intend to use the data